首页> 外国专利> GFP MUTAGENESIS AMPLIFICATION: USE OF A FLUORESCENCE-ANTIBIOTIC RESISTANCE FUSION DUAL REPORTER CONSTRUCT TO PROVIDE QUANTITATIVE AND HIGHLY SENSITIVE DETECTION OF MUTATIONS

GFP MUTAGENESIS AMPLIFICATION: USE OF A FLUORESCENCE-ANTIBIOTIC RESISTANCE FUSION DUAL REPORTER CONSTRUCT TO PROVIDE QUANTITATIVE AND HIGHLY SENSITIVE DETECTION OF MUTATIONS

机译:GFP突变扩增:使用荧光-抗性融合双报告子构建可定量和高度灵敏的突变检测

摘要

A reversion mutation assay that is unique in providing a quantitative readout for mutagenesis. This assay is based on the creation of a functional GFP-β-lactamase fusion protein as a reporter providing both antibiotic resistance and fluorescence. This dual reporter is placed in a multicopy plasmid to increase the number of targets, with a reversion site at the N-terminus. Rare mutations at the reversion site allow read-through of the fusion protein, producing both beta-lactamase (providing antibiotic resistance) and GFP (emitting fluorescence). In the presence of carbenicillin, beta-lactamase production confers a selective advantage that allows amplification of mutant plasmids, raising the level of fluorescence emitted by GFP to levels that are detectable by fluorimetry. A window of time can be found where fluorescence is proportional to the number of mutation events at the reversion site, making fluorescence a quantitative measure of mutagenesis. Quantitative (as opposed to binary) detection of mutations allows substantial savings in test sample. This has applications in drug discovery, allowing high-throughput screening for DNA-targeting compounds and early pre-screening of leads for potential carcinogenic activity. The increased sensitivity of this assay also facilitates monitoring complex environmental samples.
机译:反向突变分析,独特之处在于可为诱变提供定量读数。该测定基于产生功能性GFP-β-内酰胺酶融合蛋白作为同时提供抗生素抗性和荧光的报告基因。将该双重报告基因置于多拷贝质粒中以增加靶标的数量,并在N端具有一个回复位点。还原位点处的罕见突变允许通读融合蛋白,从而产生β-内酰胺酶(提供抗生素抗性)和GFP(发射荧光)。在羧苄青霉素存在下,β-内酰胺酶的生产具有选择性优势,可以扩增突变质粒,从而将GFP发射的荧光水平提高到荧光法可检测的水平。可以发现一个时间窗口,其中荧光与回复位点处的突变事件数量成正比,从而使荧光成为诱变的定量度量。定量(相对于二进制)突变检测可以节省大量测试样品。这在药物发现中有应用,可以进行高通量筛选靶向DNA的化合物,并提前对潜在的致癌活性进行先导筛选。该测定法灵敏度的提高还有助于监测复杂的环境样品。

著录项

  • 公开/公告号US2012302461A1

    专利类型

  • 公开/公告日2012-11-29

    原文格式PDF

  • 申请/专利权人 MANEL CAMPS;JENNIFER ALLEN;

    申请/专利号US201013504911

  • 发明设计人 JENNIFER ALLEN;MANEL CAMPS;

    申请日2010-11-02

  • 分类号G01N21/64;C12N15/63;C40B30/06;

  • 国家 US

  • 入库时间 2022-08-21 16:47:15

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号